Association of the SNPs located on RANK, RANKL and OPG; and ACPA presence or erosions in 632 patients in the ESPOIR cohort
| Rs | Genotypes | Association with ACPA | Association with erosions | ||||
|---|---|---|---|---|---|---|---|
| Number of ACPA+ (%) | χ2 test p value | Trend-test p value | Number of patients with erosions (%) | χ2 test p value | Trend-test p value | ||
| RANK | |||||||
| rs8086340 | GG | 106 (56.1) | 0.02 | 0.02 | 68 (37.8) | 0.8 | 0.8 |
| CG | 148 (46.7) | 108 (35.5) | |||||
| CC | 49 (40.8) | 42 (38.2) | |||||
| rs1805034 | TT | 103 (51.8) | 0.4 | 0.4 | 63 (32.8) | 0.2 | 0.2 |
| CT | 154 (48.3) | 121 (40.6) | |||||
| CC | 46 (43.8) | 34 (33.7) | |||||
| rs35211496 | TT | 18 (56.3) | 0.3 | 0.3 | 11 (35.5) | 1.0 | 1.0 |
| CT | 98 (51.8) | 68 (37.6) | |||||
| CC | 187 (46.3) | 139 (36.6) | |||||
| RANKL | |||||||
| rs2277438 | GG | 7 (63.6) | 0.3 | 0.3 | 2 (18.2) | 0.2 | 0.2 |
| AG | 80 (44.9) | 66 (40.2) | |||||
| AA | 217 (49.7) | 147 (35.1) | |||||
| rs1054016 | GG | 101 (45.7) | 0.04 | 0.05 | 81 (38.9) | 0.3 | 0.2 |
| GT | 142 (46.4) | 109 (37.3) | |||||
| TT | 57 (60.0) | 27 (29.7) | |||||
| rs7325635 | GG | 101 (46.3) | 0.04 | 0.05 | 81 (39.5) | 0.06 | 0.05 |
| AG | 140 (46.5) | 109 (38.0) | |||||
| AA | 64 (59.8) | 27 (26.5) | |||||
| rs7984870 | GG | 88 (45.4) | 0.03 | 0.03 | 73 (39.7) | 0.1 | 0.06 |
| CG | 142 (46.0) | 111 (38.0) | |||||
| CC | 74 (59.2) | 34 (38.3) | |||||
| OPG | |||||||
| rs2073618 | CC | 82 (50.0) | 0.8 | 0.8 | 67 (42.4) | 0.03 | 0.03 |
| CG | 145 (49.0) | 106 (38.1) | |||||
| GG | 80 (46.8) | 46 (28.4) | |||||
| rs2073617 | TT | 79 (43.9) | 0.3 | 0.3 | 52 (30.6) | 0.2 | 0.2 |
| CT | 146 (50.2) | 106 (38.7) | |||||
| CC | 74 (51.4) | 54 (38.9) | |||||
| rs10955911 | GG | 219 (51.3) | 0.2 | 0.2 | 159 (39.0) | 0.1 | 0.1 |
| AG | 76 (43.2) | 54 (33.1) | |||||
| AA | 12 (46.4) | 6 (22.2) | |||||
| rs1485305 | TT | 86 (50.0) | 0.8 | 0.8 | 65 (39.4) | 0.3 | 0.3 |
| AT | 144 (48.00) | 107 (38.1) | |||||
| AA | 65 (46.4) | 42 (31.1) | |||||
ACPA, anticitrullinated peptide antibodies; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor κ B; RANKL, receptor activator of nuclear factor κ B ligand; SNP, single-nucleotide polymorphisms.